REGN · Regeneron Pharmaceuticals, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-10-30 12:30 UTC | Regeneron Pharmaceuticals Q3 2026 Earnings Conference Call | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-09-24 |
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. |
| 2026-08-19 |
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24 th Annual Global Healthcare Conference at |
| 2026-08-19 |
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at |
| 2026-07-31 |
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. |
| 2026-07-30 |
Regeneron Reports Second Quarter 2026 Financial and Operating Results
Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD ® U.S. net sales increased 52% to a new all-time high of $596 million Libtayo ® global net sales |
| 2026-06-25 |
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. |
| 2026-06-22 |
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target action date in November 2026; European Commission decision anticipated in the second half of 2027 |
| 2026-06-04 |
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and |
| 2026-05-28 |
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients |
| 2026-05-22 |
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo |
| 2026-05-21 |
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or cardiac involvement demonstrated improvement in organ function, despite short follow-up First results |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-23 | Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum | Event |
| 2026-09-14 | Morgan Stanley 24th Annual Global Healthcare Conference | Conference |
| 2026-09-09 | 2026 Wells Fargo Healthcare Conference | Conference |
| 2026-07-30 | Regeneron Pharmaceuticals Q2 2026 Earnings Conference Call | Earnings call |
| 2026-06-12 | 2026 Annual Meeting of Shareholders | Shareholder meeting |
| 2026-06-08 | Goldman Sachs 47th Annual Global Healthcare Conference | Conference |
| 2026-05-12 | BofA Securities Health Care Conference 2026 | Conference |
| 2026-04-29 | Regeneron Pharmaceuticals Q1 2026 Earnings Conference Call | Earnings call |
| 2026-04-22 | Regeneron Roundtable: gMG & C5 Complement Program | Event |
| 2026-03-11 | Leerink Partners 2026 Global Healthcare Conference | Conference |
| 2026-01-30 | Q4 Earnings conference call (announced in 8-K) | Earnings call |
Source: https://investor.regeneron.com/